Answer
Yes. PD-L1 testing is required for its locally advanced NSCLC indication, and mismatch-repair testing determines maintenance treatment in endometrial cancer.
Sources for this answer
- IMFINZI 50 mg/mL concentrate for solution for infusion — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.